Chronic pain occurs in as many as 85% of individuals with HIV and is associated with substantial functional impairment. Little guidance is available for HIV providers seeking to address their patients' chronic pain. We conducted a systematic review to identify clinical trials and observational studies that examined the impact of pharmacologic or non-pharmacologic interventions on pain and/or functional outcomes among HIV-infected individuals with chronic pain in high-development countries. Eleven studies met inclusion criteria and were mostly low or very low quality. Seven examined pharmacologic interventions (gabapentin, pregabalin, capsaicin, analgesics including opioids) and four examined non-pharmacologic interventions (cognitive behavioral therapy, self-hypnosis, smoked cannabis). The only controlled studies with positive results were of capsaicin and cannabis, and had short-term follow-up (≤12 weeks). Among the seven studies of pharmacologic interventions, five had substantial pharmaceutical industry sponsorship. These findings highlight several important gaps in the HIV/chronic pain literature that require further research.
Introduction
Chronic pain lasting at least three months (Turk & Rudy, 1987) affects up to 30% of the US population (Institute of Medicine, 2011) . Prevalence estimates of pain in individuals with HIV are high, ranging from 39% to 85% Miaskowski et al., 2011) . In the modern treatment era, chronic pain in HIV includes the classically described syndromes of HIV neuropathy (Robinson-Papp & Simpson, 2009 ) and avascular necrosis, (Mazzotta et al., 2011) but also a high burden of regional and widespread musculoskeletal pain (Miaskowski et al., 2011) . Emerging evidence suggests that chronic pain among some patients is associated with suboptimal retention in HIV primary care and has serious health consequences, including up to 10 times greater odds of functional impairment (Merlin et al., October 2012) . Individuals with HIV who have chronic pain experience a distinct biological, psychological, and social context, as described in an adapted Biopsychosocial Framework for Chronic Pain in HIV (Merlin et al., 2013) .
Despite the uniqueness of chronic pain in individuals with HIV, little guidance is available for HIV providers seeking to address patients' pain (Dworkin et al., 2010; Finnerup et al., 2015; Krashin, Merrill, & Trescot, 2012; Parker, Stein, & Jelsma, 2014) . To address this gap, we conducted a systematic review of studies examining the impact of pharmacologic or non-pharmacologic interventions on pain or function among HIVinfected individuals with chronic pain.
Methods

Search strategy
This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses recommendations (PRISMA) (Liberati et al., 2009) . A medical librarian (LAV) searched five electronic databases. The complete PubMed search strategy, which was peer reviewed by a second librarian, is provided in the appendix, and search strategies for other databases were similar. We also reviewed articles referenced in the bibliographies of articles selected for inclusion and their forward citations, and the references of relevant systematic reviews.
Study selection
Articles were eligible for inclusion if: (1) the article reported original research (i.e., not a review or commentary); (2) subjects were HIV-infected adult human subjects; (3) subjects had chronic pain (≥3 months' duration by study inclusion criteria, or reported a mean duration of pain of ≥3 months) (Institute of Medicine, 2011); (4) study examined the impact of any exposure or intervention on a pain or functional outcome (such as pain intensity or functional status/disability), (Turk et al., 2003) ; (5) sample included ≥25 individuals with HIV, and (6) study was conducted in a "very high human development" country based on the United Nations Human Development report (Malik, 2013) . When considering whether a study was about chronic pain, we excluded studies that did not specify whether the duration of participants' pain was ≥3 months. Concurrently, we excluded studies that were not focused on pain (i.e., did not include pain as a major objective or hypothesis), and studies that had met inclusion criteria to this point but did not have at least 25 participants.
Two reviewers (JSM and HWB) screened titles and abstracts of 100 randomly selected articles for potential eligibility. Articles were excluded at this level of review if any of the six inclusion criteria were clearly unmet. Discrepancies were reviewed and resolved through refinement in inclusion criteria language. One reviewer (HWB) applied these criteria to the full set of titles/ abstracts. Next, the remaining articles were subject to full review by two independent reviewers (JSM and HWB). A third reviewer (either JLS or EJE) resolved disagreements.
Data extraction and quality assessment
All articles selected for inclusion were independently reviewed by two reviewers (JSM and either JLS, EJE, or HWB) using a data extraction instrument. Two methods were used to assess study quality. First, we used GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) (see Appendix Table A1 ) (Atkins et al., 2004) . To further characterize studies based on quality indicators that were specific to the questions of this review, we developed a checklist of 20 quality indicators similar to prior systematic reviews (see Appendix  Table A2 ) (Starrels et al., 2010) . Discrepancies were resolved by a third reviewer.
Results
Of the 1440 abstracts screened, 165 articles were eligible for full review, and 11 met criteria for inclusion (see Figure 1 ). In the text and tables, we summarize the seven studies that examined pharmacologic interventions (Table 1) (Blinderman, Sekine, Zhang, Nillson, & Shaiova, 2009; Clifford et al., 2012; Hahn et al., 2004; Koeppe, Lyda, Johnson, & Armon, 2012; Newshan & Lefkowitz, 2001; Simpson, Brown, Tobias, & Group, 2008; Simpson et al., 2010) and the four studies that examined non-pharmacologic interventions (Table 2 ) (Abrams et al., 2007; Cucciare, Sorrell, & Trafton, 2009; Dorfman et al., 2013; Trafton et al., 2012) .
Study outcomes and quality
Instruments used to assess pain and function outcomes varied considerably among studies, and included the McGill Questionnaire (Clifford et al., 2012; Dorfman et al., 2013; Hahn et al., 2004; Simpson et al., 2008) , the Brief Pain Inventory (BPI) (Newshan & Lefkowitz, 2001) , the Pain Outcomes Questionnaire (POQ) (Cucciare et al., 2009; Trafton et al., 2012) , and others. Of the 11 studies, 5 were randomized controlled trials (RCTs), 4 were pre-post studies, and 2 were observational studies without a control condition. Nine of the 11 studies had a GRADE score of 1 (very low) or 2 (low) (see Tables  A1 and A2 in the Appendix). The median number of quality indicators met was 9 out of 20 (range 4-18). Common quality concerns were lack of long-term follow-up, intention-to-treat analyses, or randomization.
Studies were generally small; only three had more than 100 participants (Clifford et al., 2012; Simpson et al., 2008; Simpson et al., 2010) . No studies were conducted completely in the current HIV treatment era, defined as 2006-present. Only five studies followed participants for six months or longer (Blinderman et al., 2009; Koeppe et al., 2012; Simpson et al., 2008; Simpson et al., 2010; Trafton et al., 2012) , and two followed participants for a year or longer (Blinderman et al., 2009; Koeppe et al., 2012) . Of the seven studies of pharmacologic interventions, five had substantial pharmaceutical company sponsorship (Clifford et al., 2012; Hahn et al., 2004; Newshan & Lefkowitz, 2001; Simpson et al., 2008; Simpson et al., 2010) .
Summary of study findings
Pharmacologic interventions
Of the seven studies of pharmacologic interventions, four were RCTs, all of which evaluated non-opioid medications. In two randomized trials of anticonvulsants, neither gabapentin nor pregabalin was more effective than placebo in treating HIV-associated neuropathic pain (Hahn et al., 2004; Simpson et al., 2010) . Two randomized trials of a high dose capsaicin patch vs. placebo for HIV-infected individuals with neuropathic pain found a greater reduction in pain on the numeric pain scale in the intervention group than in the placebo group (mean reduction 22.8% vs. 10.7% in one study, and 31.2% vs. 25.3%); however, follow-up was short (12 weeks) and both studies allowed participants to pre-medicate with lidocaine and address capsaicinrelated pain with opioids (Clifford et al., 2012; Simpson et al., 2008) . Of the remaining three pharmacologic studies, two found reductions in pain after adding opioids for individuals already taking opioids (Blinderman et al., 2009; Newshan & Lefkowitz, 2001) , and one found higher pain scores after a mean of five years on opioids (Koeppe et al., 2012) .
Non-pharmacologic interventions
Of the four studies of non-pharmacologic interventions, the only RCT examined smoked cannabis vs. placebo in patients with neuropathic pain over a one week followup period. This study found that median pain on a visual analog scale (VAS) decreased twice as much (34% vs. 17%) in the cannabis group compared to the placebo group. The other three non-pharmacologic studies were pre-post studies of behavioral interventionstwo studies of cognitive behavioral therapy (CBT) found small improvements in pain at 12 and 24 weeks but were limited by poor adherence, and a study of self-hypnosis for neuropathic pain found a small reduction in pain at 10 weeks.
Discussion
Despite the clinical burden of chronic pain in this population, this systematic review identified only 11 studies that examined treatments for chronic pain in individuals with HIV. Most were low or very low quality. Although much of chronic pain in the current HIV treatment era is musculoskeletal, over half of the studies focused on neuropathic pain. Additionally, despite prevalent use of opioids among HIV-infected patients with pain, only three low or very low quality studies examined opioids. The only higher quality study (GRADE 3, moderate quality) that found significant improvements in pain was a short-term study of capsaicin. Based on these findings, though some interventions hold promise, there is insufficient evidence to guide providers in the care of individuals with HIV and chronic pain, and future research is needed. Though opioids are commonly prescribed in individuals with HIV and chronic pain, the evidence to support this is limited and results are mixed. These findings are consistent with the state of evidence about opioids in general populations (Chou et al., 2015) . Notably, among the seven studies of pharmacologic interventions, the five highest quality studies had substantial pharmaceutical industry sponsorship (Clifford et al., 2012; Hahn et al., 2004; Newshan & Lefkowitz, 2001; Simpson et al., 2008; Simpson et al., 2010) . While such sponsorship is often necessary for such trials to be carried out, it is important to note the potential for conflict of interest.
Surprisingly, we only identified two low quality, shortterm studies of behavioral interventions, which are among the most effective chronic pain treatments in the general population (Turk, Wilson, & Cahana, 2011) . The success of a behavioral intervention is heavily influenced by how well it is tailored to the target population (Bartholomew, Parcel, Kok, Gottleib, & Fernandez, 2011) . Therefore, future investigations should focus on developing behavioral interventions specifically for individuals with HIV. It is also noteworthy that while HIV is an indication for prescribing medical cannabis in some states, we identified only one study that met our inclusion criteria and investigated smoked cannabis for chronic pain in individuals with HIV.
The primary limitation of this study is that the inclusion criteria employed to ensure methodological rigor may have excluded relevant studies. For example, we excluded studies that did not report sufficient detail to identify participants as having chronic pain (Evans et al., 2007; Shlay et al., 1998) , including studies that may have been included in prior systematic reviews on neuropathic pain. This highlights an additional limitation of the literature in this area, specifically, that there is no standardized research definition of chronic pain and high variability across studies. Similarly, there was a lack of consistency in measurement of pain and function outcomes across studies.
In sum, despite the high prevalence and unique features of chronic pain in HIV, the pace of research on chronic pain in HIV-infected individuals has not matched the clinical need. Future studies of pharmacologic and non-pharmacologic interventions in individuals with HIV are urgently needed. (6) #1 AND #2 AND #3 (7) #5 NOT #4 (8) #6 AND #7 Note: We also reviewed articles referenced in the bibliographies of articles selected for inclusion and their forward citations, and the references of relevant systematic reviews. Serious limitations: Inadequate control condition/pre-post design, lack of long-term follow-up, concern for regression to the mean 1 Cucciare, 2009 2 −1 pre-post, small study, "p < .05", regression to the mean issue, confounding because those with improved function more likely to attend, and not clear how drop-outs were different; that is, excluding them biases towards seeing an improvement when none may have existed, no power calculation, short follow-up 1 Dorfman, 2013 2 −1 pre-post, no multivariable analyses 1 *4 = randomized trial, 3 = quasi-randomized, 2 = observational (including pre-post), 1 = any other evidence. †Adjustments based on: Table A2 . Study quality according to 20-item checklist.
